Saturday, July 11, 2026

Drug profile · INN

fosaprepitant meglumine

fosaprepitant meglumine (PROEMEND) is a neurokinin 1 receptor antagonist.

PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — fosaprepitant meglumine
Class
Route
Patents
0
Programs
0
Data quality
0.78

Quick answer

fosaprepitant meglumine (PROEMEND) is a neurokinin 1 receptor antagonist.

Key facts

INN fosaprepitant meglumine
Brand PROEMEND
Mechanism Neurokinin 1 receptor antagonist
Target Substance-P receptor

Mechanism of action

Neurokinin 1 receptor antagonist

Primary target: Substance-P receptor

Approval history

Authority Status Date
PMDA approved

Related & competitor drugs

  1. aprepitant Alimentary tract and metabolism (A04)
  2. fosaprepitant dimeglumine Neurokinin 1 receptor antagonist
  3. tradipitant Neurokinin 1 receptor antagonist
  4. elinzanetant Neurokinin 3 receptor antagonist
  5. fosnetupitant chloride hydrochloride Neurokinin 1 receptor antagonist
  6. netupitant Alimentary tract and metabolism (A04)

Frequently asked questions

What is fosaprepitant meglumine?

fosaprepitant meglumine (PROEMEND) is a neurokinin 1 receptor antagonist.

What is the brand name for fosaprepitant meglumine?

PROEMEND is a marketed brand name for fosaprepitant meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.